Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in ...
2d
On-demand video webcast now available here TAMPA, FL / ACCESS Newswire / February 19, 2025 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 registration-stage immune-oncology company dev ...
Zacks.com on MSN9d
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in FocusExelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...
AI hardware stocks dived recently thanks to DeepSeek's AI model launch. Meta Platforms has a dominant advertising business that fuels its other investments. MercadoLibre's stock looks incredibly ...
The company's stock recently dropped 9% following a disappointing update on the vaccine business in China, further emphasizing the risks of overdependence on one blockbuster drug. Keytruda ...
The quote below is from a Wall Street Journal interview ... Unfortunately, investors seeking shelter in healthcare stocks for dividend growth and capital gains have been unable to outperform ...
Zacks.com on MSN17d
Merck Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '25 ViewMerck MRK reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.72, which beat the Zacks Consensus Estimate of $1.69. In the year-ago period, management reported adjusted EPS of 3 cents ...
Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...
Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...
Keytruda sales grew 19% YoY to $7.84B ... upon completion of the technology transfer for MK-2010. Price Action: MRK stock is down 7.81% at $92.01 premarket at the last check on Tuesday.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here ... to have been driven by blockbuster cancer drug Keytruda, like in several previous quarters, aided by ...
MRK’s Study on Keytruda Lenvima Combo Misses OS Goal Merck ... Here’s how the eight major stocks performed in the previous five trading sessions. Image Source: Zacks Investment Research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback